Spero therapeutics awarded up to an additional $12.9 million by barda to support the development of orally administered tebipenem pivoxil in pediatric patients

New award option exercised by barda brings the total potential funding from its existing contract with spero up to $59.7 million new award option exercised by barda brings the total potential funding from its existing contract with spero up to $59.7 million
SPRO Ratings Summary
SPRO Quant Ranking